Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Immunogenomics Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The immunogenomics market has experienced rapid expansion in recent years. This market is forecasted to grow from $6.09 billion in 2025 to $7.07 billion in 2026, at a compound annual growth rate (CAGR) of 16.1%. The historical increase observed in this sector can be attributed to several factors, including advancements in genomic sequencing technologies, an improved understanding of immune-related genetic variations, the broadening of oncology and infectious disease research, increased funding for research, and the availability of high-throughput genomic tools.
The immunogenomics market is projected to experience substantial expansion in the coming years. Its value is anticipated to reach $12.73 billion by 2030, achieving a compound annual growth rate (CAGR) of 15.8%. This growth during the forecast period is fueled by several factors, including the escalating demand for precision medicine solutions, the ongoing development of personalized vaccines and immunotherapies, the broadening of translational immunogenomics research, the increasing integration of multi-omics data, and the wider adoption of cloud-based genomic analytics. Key trends observed in this period encompass the growing uptake of next-generation sequencing for immune profiling, the expanded application of bioinformatics tools for analyzing immune data, an intensified focus on personalized immunotherapies, the enlargement of genomic databases dedicated to immune research, and the improved integration of AI in immunogenomic investigations.
Get A Free Sample Report With In-Depth Market Insights:
Immunogenomics Market Development Factors: What’s Supporting Demand?
The rising occurrence of infectious diseases is projected to stimulate the expansion of the immunogenomics market moving forward. Infectious diseases are defined as ailments caused by harmful microorganisms, such as bacteria, viruses, fungi, or parasites, capable of spreading from one individual to another directly or indirectly. The upward trend in infectious disease prevalence is attributed to increased travel, which facilitates the rapid dissemination of pathogens across borders. Immunogenomics improves the management of infectious diseases by enabling precise analysis of host immune responses and genetic susceptibility. It reduces the need for trial-and-error in treatment by identifying immune factors specific to each patient, thereby enhancing diagnostics, vaccine development, and personalized therapeutic strategies. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government agency, tuberculosis (a contagious bacterial infection that primarily affects the lungs) cases in England increased to 4,850 in 2023, representing a 10.7% rise from 4,380 cases in 2022. Consequently, the growing prevalence of infectious diseases is driving the growth of the immunogenomics market.
Immunogenomics Market Segment Landscape: Which Areas Lead Development?
The immunogenomics market covered in this report is segmented –
1) By Product Type: Instruments, Consumables, Software, Services
2) By Technology: Next-Generation Sequencing, Microarray, Polymerase Chain Reaction, Other Technologies
3) By Application: Oncology, Infectious Diseases, Autoimmune Disorders, Transplantation, Other Applications
4) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By Instruments: Sequencers, Microarray scanners, Flow cytometers
2) By Consumables: Reagents, Kits, Assay panels
3) By Software: Data analysis software, Bioinformatics tools, Visualization platforms
4) By Services: Sequencing services, Genomic profiling, Bioinformatics support
Immunogenomics Market Transformation Trends: What Innovations Are Driving Change?
Leading companies active in the immunogenomics market are channeling their efforts into developing advanced solutions, including vaccine target prediction systems, which facilitate automated, end-to-end vaccine design and optimize vaccine constructs by ensuring an optimal antigen sequence. The vaccine target prediction system functions as a computational platform that utilizes bioinformatics algorithms alongside genomic and immunomic data to pinpoint potential antigen molecules from pathogens or cancer cells, subsequently analyzing their structural properties to prioritize and select the most suitable vaccine candidates with the highest capacity to trigger protective immune responses. For example, in September 2024, Evaxion Biotech A/S, a biotechnology company based in Denmark specializing in artificial intelligence-driven immunotherapy and vaccine development, launched its clinically validated AI-Immunology platform, an enhanced EDEN artificial intelligence prediction model that incorporates a novel toxin antigen predictor. This enhancement improves the accuracy and reliability of identifying bacterial toxin antigens for developing next-generation bacterial vaccines. Additionally, the platform is capable of simulating the immune system to create personalized and next-generation immunotherapies and has demonstrated strong correlations between its artificial intelligence-generated predictions and clinical outcomes.
Immunogenomics Market Industry Leaders And Competitive Landscape
Major companies operating in the immunogenomics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Illumina Inc., BGI Group, GenScript Biotech Corporation, CareDx Inc., Oxford Nanopore Technologies plc, Genewiz LLC, Adaptive Biotechnologies Corporation, GenomOncology LLC, Personalis Inc., Variantyx Inc., CD Genomics Inc., Sengenics Corporation, GeneCentric Therapeutics Inc., Immunogenomics Inc., ImmuQuad Biotechnologies Inc., Neomics Pharmaceuticals LLC, Yemaachi Biotech Ltd., BioAnalytica Biotechnology Systems Inc.
View The Full Immunogenomics Market Report:
Immunogenomics Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the immunogenomics market in 2025. The regions covered in the immunogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
